NCT03825965View on ClinicalTrials.gov

Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT

PHASE3CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

February 25, 2025

Study Completion Date

February 25, 2025

Conditions
Knee Osteoarthritis
Interventions
DRUG

MPL-001 (CBD: THC 25:1)

25:1 cannabidiol (CBD): tetrahydrocannabinol (THC) oral formulation, with a concentration of 50 mg/mL CBD and 2 mg/mL THC, oil- Liquid for oral use

DRUG

Placebo oil for oral use

Placebo is Medium-chain triglycerides oil with identical features (in appearance, flavour, and odour) to the MPL-001 oil.

Trial Locations (2)

L8N 4A6

St. Joseph's Healthcare Hamilton, Hamilton

M5B 1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

St. Joseph's Healthcare Hamilton

OTHER

collaborator

Hamilton Health Sciences Corporation

OTHER

lead

McMaster University

OTHER

NCT03825965 - Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT | Biotech Hunter | Biotech Hunter